Cancer drug delivery最新文献

筛选
英文 中文
In vitro chemosensitivity testing using the multicellular tumor spheroid model. 多细胞肿瘤球体模型体外化疗敏感性试验。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.63
D J Kerr, T E Wheldon, A M Kerr, S B Kaye
{"title":"In vitro chemosensitivity testing using the multicellular tumor spheroid model.","authors":"D J Kerr,&nbsp;T E Wheldon,&nbsp;A M Kerr,&nbsp;S B Kaye","doi":"10.1089/cdd.1987.4.63","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.63","url":null,"abstract":"<p><p>Using growth delay and clonogenic cell survival as end points, we have shown that the 3-dimensional structure of human lung tumour spheroids confers a degree of resistance to the anthracyclines doxorubicin and 4'-deoxydoxorubicin, relative to cells grown as monolayer. 4'-deoxydoxorubicin induces a longer growth delay and greater clonogenic cell kill than doxorubicin in spheroids, although it is no more cytotoxic in monolayer. Using fluorescent microscopy we have demonstrated, qualitatively, that lipophilic anthracycline analogues partition into the spheroid more rapidly and to a greater degree than doxorubicin. It is apparent that penetration is an important aspect of anthracycline drug resistance in spheroids, and the spheroid model may represent a better in vitro system for testing lipophilic analogues of cytotoxic drugs.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 2","pages":"63-74"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.63","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14552098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Schedule-dependent toxicity of tumor necrosis factor in rodents. 啮齿动物肿瘤坏死因子的时间表依赖性毒性。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.159
J D Liddil, R T Dorr
{"title":"Schedule-dependent toxicity of tumor necrosis factor in rodents.","authors":"J D Liddil,&nbsp;R T Dorr","doi":"10.1089/cdd.1987.4.159","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.159","url":null,"abstract":"<p><p>The effect of recombinant human tumor necrosis factor-alpha (rhTNF-alpha) on rodent hematopoietic precursors and hepatocytes was evaluated. rhTNF-alpha appears to have minimal toxic effects on isolated hepatocytes and on granulocyte-macrophage colony-forming units (CFU-GM) in vitro. It does, however, show a dose- and schedule-dependent inhibition of pluripotent bone marrow stem cells in mice. This was most evident with prolonged continuous infusion schedules. In contrast, single daily injections of rhTNF-alpha did not depress bone marrow or peripheral blood counts, although slight elevations in hepatic enzyme levels were apparent. These studies suggest that continuous infusions of rhTNF-alpha in man may produce enhanced bone marrow suppression over equivalent bolus doses.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 3","pages":"159-67"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14575855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Management of infectious complications of intraventricular reservoirs in cancer patients: low incidence and successful treatment without reservoir removal. 肿瘤患者脑室内储液器感染性并发症的处理:低发病率和成功治疗而不移除储液器。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.105
P A Dinndorf, W A Bleyer
{"title":"Management of infectious complications of intraventricular reservoirs in cancer patients: low incidence and successful treatment without reservoir removal.","authors":"P A Dinndorf,&nbsp;W A Bleyer","doi":"10.1089/cdd.1987.4.105","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.105","url":null,"abstract":"<p><p>At the time of analysis, the first 30 patients with Ommaya reservoirs (OR) at the Children's Orthopedic Hospital and Medical Center in Seattle, Washington had had 32 reservoirs for a mean duration of 28 months. In all, the reservoir chambers had been punctured for either diagnostic or therapeutic purposes a total of 1,287 times with a mean of 40 injections per reservoir and 1.4 injections per month. Six reservoir infections were diagnosed in five patients--a rate of one infection for every 153 reservoir-months. Four infections were attributed to reservoir use--a rate of one infection for every 322 reservoir entries, and less than one infection in 900 entries when a standard aseptic protocol for sampling and injection was applied. There was no correlation between infectious complications and the frequency with which reservoirs were injected, but there was evidence that some of the infections resulted from incomplete compliance with recommended technique for skin preparation and reservoir entry. Four infections were treated successfully with intravenous and intra-reservoir antibiotics without reservoir removal. Only one reservoir had to be removed because of persistent infection. Two other reservoirs were removed because of trauma and malfunction. Twenty-seven patients (90%) retained their original reservoir, up to 9.5 years after implantation. Intraventricular chemotherapy via an indwelling subcutaneous reservoir is a preferred method for delivery of intrathecal chemotherapy, with an acceptable infection risk relative to the benefits of patient comfort and therapeutic efficacy.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 2","pages":"105-17"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14605190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions. 甲氨蝶呤输注后甲氨蝶呤和7-羟基甲氨蝶呤的药动学。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.177
P Bore, A Iliadis, J Catalin, S Just, J P Cano
{"title":"Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate after methotrexate infusions.","authors":"P Bore,&nbsp;A Iliadis,&nbsp;J Catalin,&nbsp;S Just,&nbsp;J P Cano","doi":"10.1089/cdd.1987.4.177","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.177","url":null,"abstract":"<p><p>Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and 7-hydroxy-methotrexate in plasma were 15.02 and 15.19 hours respectively. The area under concentration-time curve was 723.8 +/- 196.4 microM x h for methotrexate and 598.1 +/- 212.5 microM x h for 7-hydroxy-methotrexate. The total average urinary excretions of methotrexate and 7-hydroxy-methotrexate over a 96 hour period were 52% and 5.4% respectively. Urinary clearance of methotrexate was 3.46 +/- 1.4 1/h. In contrast, urinary excretion of 7-hydroxy-methotrexate was not linear. These results confirm the protein binding of metabolite to serum albumin and may suggest that distribution of 7-hydroxy-methotrexate is different from unchanged drug or that the metabolite can be eliminated by another route, such as bile.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 3","pages":"177-83"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14626782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Restoration of drug sensitivity by nitroxazepine hydrochloride in P388 murine leukemia cells resistant to adriamycin. 盐酸硝基沙西平对阿霉素耐药小鼠白血病细胞P388的药物敏感性恢复。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.1
M P Chitnis, S G Pradhan, K Satyamoorthy, V S Basrur
{"title":"Restoration of drug sensitivity by nitroxazepine hydrochloride in P388 murine leukemia cells resistant to adriamycin.","authors":"M P Chitnis,&nbsp;S G Pradhan,&nbsp;K Satyamoorthy,&nbsp;V S Basrur","doi":"10.1089/cdd.1987.4.1","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.1","url":null,"abstract":"<p><p>Attempts were made to reverse the acquired resistance of P388 murine leukemia utilizing non-toxic concentration of nitroxazepine hydrochloride, an antidepressant. The effect of nitroxazepine hydrochloride on the intracellular accumulation of adriamycin and the inhibition of DNA synthesis were studied in these cells. The survival of mice bearing adriamycin-resistant P388 murine leukemia cells treated in vitro with nitroxazepine hydrochloride, adriamycin and a combination of the two drugs was also investigated. The results show that treatment of these cells with nitroxazepine hydrochloride significantly enhanced (1) the intracellular accumulation of adriamycin, (2) inhibition of DNA biosynthesis, and (3) the survival of mice transplanted with adriamycin-resistant P388 murine leukemia cells treated in vitro with a combination of nitroxazepine hydrochloride and adriamycin. The mechanism of restoration of drug sensitivity by nitroxazepine hydrochloride in adriamycin-resistant P388 cells could be due to an enhanced intracellular accumulation of adriamycin. The implications of the present investigations are promising, leaving hope for the utility of nitroxazepine hydrochloride in restoring drug sensitivity in adriamycin-resistant tumors.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14728589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats. 环磷酰胺对大鼠抗黑素瘤单克隆抗体-蓖麻毒素A链免疫毒素免疫原性的影响。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.151
S Harkonen, R Mischak, H Lopez, J Stoudemire
{"title":"Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.","authors":"S Harkonen,&nbsp;R Mischak,&nbsp;H Lopez,&nbsp;J Stoudemire","doi":"10.1089/cdd.1987.4.151","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.151","url":null,"abstract":"<p><p>This study was performed to determine the effect of treatment with cyclophosphamide (CY) on the formation of antimurine and anti-ricin A chain antibodies in rats treated with a murine monoclonal antimelanoma antibody-ricin A chain immunotoxin (IT). Animals received treatment with either IT alone or IT plus CY. IT treatment consisted of daily IV injections at a dose of 1 mg/kg/day on days 0, 1, 2, 3, 4. CY treatment consisted of a 25 mg/kg IP dose on day -1 followed by daily IP doses of 5 mg/kg/day on days 0, 1, 2, 3, 4. Antibody binding activities in treated animals were measured by enzyme-linked immunosorbent assay and reported as optical density values. Rats treated with IT plus CY had lower binding activity on day 7 (0.09 vs 0.6; p = .02), day 14 (0.42 vs 1.22; p = .001), and day 21 (0.11 vs 1.3; p = .001) compared to rats treated with IT alone. Lower levels of anti-ricin A chain binding activity were observed in CY treated rats on day 14 (0.35 vs 1.25; p = .001), but not on day 7 or day 21. These results indicate that treatment with CY can abrogate the immune response to murine antibody and partially abrogate the immune response to ricin A chain.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 3","pages":"151-7"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14626781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. 慢性低剂量甲氨蝶呤后恒河猴叶酸和多谷氨酸组织水平。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.25
N J Winick, B A Kamen, F M Balis, J Holcenberg, C M Lester, D G Poplack
{"title":"Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate.","authors":"N J Winick,&nbsp;B A Kamen,&nbsp;F M Balis,&nbsp;J Holcenberg,&nbsp;C M Lester,&nbsp;D G Poplack","doi":"10.1089/cdd.1987.4.25","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.25","url":null,"abstract":"<p><p>Methotrexate (MTX), a mainstay in the treatment of acute lymphoblastic leukemia, is associated with both hepatic and neurologic toxicity. Like a folate, MTX is metabolized to polyglutamated derivatives (MTXGlun) with long intracellular half-lives. These metabolites may contribute to MTX toxicity through a direct effect on cellular metabolism or indirectly through a perturbation of folate homeostasis. To better define the effects of chronic MTX treatment, tissue levels of MTX, MTXGlun, and folate were measured in three monkeys treated with weekly intramuscular MTX for 1 year. Greater than 80% of the total tissue MTX found was in the form of polyglutamated derivatives. Most of these derivatives were MTXGlu3-5 but Glu6-7 were easily detectable. Total tissue folates were measured in liver, kidney, brain and testis with MTX treated animals having a 90% loss of total folate in brain tissue. This is of special interest since inborn errors of folate metabolism are often associated with severe neurologic abnormalities.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 1","pages":"25-31"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13585703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres. 肝动脉注射后5-氟尿嘧啶与可降解淀粉微球在大鼠肝腺癌RNA中的掺入。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.169
H Teder, C Erichsen, P I Christensson, P E Jönsson, U Stenram
{"title":"5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres.","authors":"H Teder,&nbsp;C Erichsen,&nbsp;P I Christensson,&nbsp;P E Jönsson,&nbsp;U Stenram","doi":"10.1089/cdd.1987.4.169","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.169","url":null,"abstract":"<p><p>The effect of degradable starch microspheres (DSM) on the cellular incorporation of 5-fluorouracil (FUra) was studied in rats with solitary liver tumours. 3H-labelled FUra [0.78 mg (6000 nmol)/kg b.wt.] was injected with saline or mixed with DSM, into the hepatic artery. Labelling of the acid soluble fraction (ASF), RNA and DNA of tumour, liver, bone marrow and small intestine was measured 60 minutes after injection. The DSM had no significant effect on the incorporation of FUra into the ASF or RNA, neither in tumour nor liver tissue. Regarding the tumour/normal tissue ratios of specific radioactivities, there was with DSM a higher tumour/liver and a higher tumour/bone marrow ratio in the ASF, indicating an increased tumour drug exposure with DSM. However, this was not accompanied by any significant increase in drug anabolism.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 3","pages":"169-76"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13599269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Resistance of V79 multicell spheroids to mitoxantrone: drug uptake and cytotoxicity. V79多细胞球体对米托蒽醌的耐药性:药物摄取和细胞毒性。
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.201
T J Bichay, W R Inch
{"title":"Resistance of V79 multicell spheroids to mitoxantrone: drug uptake and cytotoxicity.","authors":"T J Bichay,&nbsp;W R Inch","doi":"10.1089/cdd.1987.4.201","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.201","url":null,"abstract":"<p><p>We have previously shown that V79 multicell spheroids are resistant to the anthracenedione mitoxantrone (1). In this paper we demonstrate that this resistance is not solely due to restricted drug penetration into the spheroid, but also to an altered intrinsic resistance of the cells when grown as a three-dimensional structure. We have studied the uptake and toxicity of mitoxantrone in V79-OCF4 monolayers, 100 micron spheroids, 650 micron spheroids, and outer and inner cells of 650 micron spheroids. The LD90 for cells exposed as monolayers to mitoxantrone for two hours was 0.016 microgram/ml, 0.055 microgram/ml for 100 micron spheroids, 1.5 micrograms/ml for outer spheroid cells and 6.2 micrograms/ml for inner spheroid cells. Uptake of [14C]mitoxantrone was linear for all populations with no plateau up to the highest doses used. The uptake of drug required to kill 90% of the cells in a population (UP90) of monolayers was 3.7 ng/10(6) cells, 10.7 ng/10(6) cells for 100 micron spheroids, 169 ng/10(6) cells for outer spheroid cells, and 146 ng/10(6) cells for inner spheroid cells. The relative resistance of spheroids compared to monolayers, based on drug concentration in the medium, was 3.4 for small spheroids, 92 for outer cells, and 390 for inner cells. When cell survival was normalized to drug uptake, the relative resistance of spheroids to monolayers was 2.9 for small spheroids, 46 for outer cells and 40 for inner cells of large spheroids. The data demonstrate that the resistance of multicell spheroids to mitoxantrone is not solely due to restricted drug penetration into the cell aggregate but is also due to a spheroid-induced altered intrinsic resistance of the V79 cells.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 4","pages":"201-11"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.201","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14578495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. 转移性黑色素瘤患者对蓖麻毒素a链免疫毒素的体液免疫反应
Cancer drug delivery Pub Date : 1987-01-01 DOI: 10.1089/cdd.1987.4.245
A A Hertler, L E Spitler, A E Frankel
{"title":"Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.","authors":"A A Hertler,&nbsp;L E Spitler,&nbsp;A E Frankel","doi":"10.1089/cdd.1987.4.245","DOIUrl":"https://doi.org/10.1089/cdd.1987.4.245","url":null,"abstract":"<p><p>Immunotoxins, hybrid molecules consisting of a monoclonal antibody linked to a polypeptide toxin have shown anti-tumor activity in both animal models and early clinical trials. However, their potential value in the treatment of human cancer may be limited by the development of host antibodies against the conjugate. Such antibodies could potentially alter immunotoxin pharmacokinetics and pharmacodynamics as well as precipitate serum sickness or anaphylaxis. Using a radioimmunoassay we have measured serial anti-ricin A chain (anti-RTA) and anti-murine immunoglobulin (anti-MIG) titers in 22 patients who received the anti-melanoma immunotoxin XomaZymeR-Mel. Significant titers of anti-RTA and/or anti-MIG were detected in 17 of 21 evaluable patients. Of the four patients not developing antibodies, two were likely immunosuppressed secondary to dexamethasone, and CCNU and dexamethasone respectively. Both patients who received immunotoxin at a time when they had detectable anti-immunotoxin antibodies experienced infusion reactions consistent with immune mediated allergic responses. There was a decrease in peak immunotoxin level in the one patient who had serum immunotoxin levels measured at a time when anti-RTA was present. Strategies to suppress the human immune response to immunotoxins are required before repetitive courses of immunotoxin of this design may be administered.</p>","PeriodicalId":77686,"journal":{"name":"Cancer drug delivery","volume":"4 4","pages":"245-53"},"PeriodicalIF":0.0,"publicationDate":"1987-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cdd.1987.4.245","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14625099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信